Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China

por Shi, Yafei, Chen, Wei, Zhang, Yujun, Bo, Mingming, Li, Chunyu, Zhang, Mingyu, Li, Guohui
Publicado 2021

A Comprehensive Analysis of Metabolomics and Transcriptomics Reveals Novel Biomarkers and Mechanistic Insights on Lorlatinib Crosses the Blood-Brain Barrier

por Chen, Wei, Li, Chunyu, Shi, Yafei, Zhang, Yujun, Jin, Dujia, Zhang, Mingyu, Bo, Mingming, Li, Guohui
Publicado 2021

Metabolomics Combined with Network Pharmacology-Based Strategy to Reveal the Underlying Mechanism of Zhenhuang Submicron Emulsion in Treating Oropharyngeal Mucositis Complications...

por Chen, Wei, Li, Chunyu, Jin, Dujia, Shi, Yafei, Zhang, Mingyu, Bo, Mingming, Qian, Di, Wang, Mengyang, Li, Guohui
Publicado 2022

Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small...

por Shi, Yafei, Qian, Di, Li, Yanhui, Chen, Wei, Bo, Mingming, Zhang, Mingyu, Shi, Jianglei, Jia, Bei, Dai, Yuanyuan, Li, Guohui
Publicado 2023